4   Intersect ENT  |  1555  Adams Drive |  Menlo Park, CA 94 025  |  650.641.2100 www.PROPELOPENS.com   Chronic Sinusitis: One of America’s Most Common Health Conditions  31 million people are afflicted with chronic sinusitis each year,    making it one of the most common health  conditions in the United States. The sinuses are air  -    filled cavities located within the bones around the nose and eyes that allow for natural  ventilation and drainage.   In Chronic Sinusitis ,  the sinus linings beco   me inflamed,   blocking the natural  drainage passageways and leading to chronic infections and nasal obstruction.     Patients with chronic sinusitis often suffer from debilitating symptoms such as  facial pain or pressure, nasal  congestion and difficulty br  eathing, discolored nasal discharge, loss of smell and taste, headache, fatigue  and depression. A Need to Improve Treatment Outcomes Chronic sinusitis often requires a complex combination of surgical and medical treatments.  When sinusitis  does not respo nd to medications, surgery to enlarge the openings that drain the sinuses may be an option. Each year, 500,000 patients undergo ethmoid   sinus surgery to treat the condition. Although sinus surgery is  effective, the majority of patients experience recurre   nt symptoms within the first year; as many as 25 percent  then undergo revision surgery due to recurrent obstruction of the sinus cavity. Chronic Sinusitis Patients Have A New Weapon  - PROPEL The goal of surgical treatment for chronic sinusitis is to enlarge the inflamed or obstructed sinus  passageways. Post - surgery  check - ups are required to inspect  the sinus cavities  to monitor for inflammation  and  scarring and treat accordingly with surgery a  nd/or oral steroids . The dissolvable PROPEL Steroid - Releasing Implant is the first in a new category of products offering  localized, controlled delivery of steroid directly to the sinus tissue    to maintain the openings created in  surgery .   Applying princ iples of coronary drug - eluting stents to sinusitis sufferers, the spring   -   like implants gradually  deliver an advanced steroid with anti      -    -inflammatory propertie s (  m ometasone furoate ) directly to the sinus  lining, then dissolve into the body following endoscop   ic sinus surgery. The result is improved surgical  outcomes, reducing the need for additional surgical procedures and for systemic steroids, which can have  serious side effects . Three rigorous clinical trials have demonstrated that the implant is safe and m   aintains the results of sinus  surgery by  propping open the sinus cavities and  decreasing post  -  operative  scarring and inflammation .   Reducing these factors is proven to improve long   -   term outcomes   and to redu  ce the need for repeat surgery  and oral steroids, which can have serious side effects.    PROPEL is the only product used in sinus surgery to  be supported by level 1  - A evidence. National Health Interview Survey 2006. CDC National Center for Health Statistics. Series 10 Number 235 . Rosenfeld et al,. Oto – HNS. 2007; 137:S1 - S31. Schaitkin BM, May M, Shapiro A: et al,. Laryngoscope. 1993; 103: 1117 - 20. Pilot study results:  Murr AH, Smith TL, Hwang PH, et al. IFAR. 2011;1:23 – 32. ; ADVANCE II clinical trial:   Marple BF, Smith TL, Han JK et  al.  Otolaryngol Head Neck Surg. 2012; 146(6 ) 1004 - 1011 . ; Meta - analysis:  Han JK, Marple BF, Smith TL et al IFAR.  2012;  2 :271 - 279 . Kennedy DW, Wright ED, Goldberg AN. Laryngoscope. 2000;110:29 – 31 . The PROPEL Sinus Implant is intended for use following et h  moid sinus  surgery to maintain patency . For more information consult your  physician or visit  www.intersectENT.com to view information including indication s , contraindications, warnings, precautions and adverse  events. Caution:  Federal law (USA) restr icts this product to sale by or on the order of a physician. 2013 © Intersect ENT Inc. All rights reserved. INTERSECT ENT  ® and PROPEL ® are registered trademarks of Intersect ENT, Inc. News
Johnson City, Tennessee
Ear Nose & Throat Associates physicians now offering a New Option for Chronic Sinusitis Patients PROPEL Steroid-Releasing Implant  
Home Our Staff Location Forms & Notices FAQ’s Speech ENT Services News News